Pulmonary embolism (PE) represents the third leading cause of cardiovascular mortality.
The technological landscape for management of acute intermediate-and high-risk PE is …

Pulmonary embolism is the third most common cause of death from cardiovascular disease
after heart attack and stroke. Sequelae occurring after venous thromboembolism include …

Pulmonary embolism is an important clinical entity with considerable mortality despite
advances in diagnosis and treatment. In the present article, the authors offer a …

Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure greater than
20 mm Hg and classified into five different groups sharing similar pathophysiologic …

Background—Chronic thromboembolic pulmonary hypertension leads to pulmonary
hypertension and right-sided heart failure. The purpose of this study was to investigate the …

Background: Distal-type chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal
disease for which a new therapeutic strategy needs to be developed. We examined the …

Intermediate-risk (submassive) pulmonary embolism (PE) describes normotensive patients
with evidence of right ventricular compromise, whereas high-risk (massive) PE comprises …

Limited numbers of operated patients with chronic thromboembolic pulmonary hypertension
(CTEPH) are refractory to pulmonary endarterectomy (PEA) and experience persistent …

Balloon pulmonary angioplasty (BPA) has been reported to improve haemodynamics and
functional capacity, with an acceptable risk, in patients with chronic thromboembolic …

Pulmonary embolism is the third most common cardiovascular disease after myocardial
infarction and stroke. The death rate from pulmonary embolism exceeds the death rate from …